ESTRO 2025 - Transformative innovation through partnership
We were delighted to have four posters, and one oral presentation accepted at ESTRO 2025 (European Society for Therapeutic Radiology and Oncology).
The conference was a valuable platform enabling us to share the clinical advantages of MR-guided SABR and were excited to present our latest findings. You can explore and download the materials below:
- MR-guided adaptive radiotherapy (SMART) for localised pancreatic cancer – Download PDF
- MR-guided adaptive radiotherapy (SMART) reirradiation for liver metastases – Download PDF
- Quantifying the benefit of daily on-table adaptation in reducing gastric and duodenal NTCP during stereotactic MR guided adaptive radiotherapy – Download PDF
- Dosimetric outcomes of ultra-hypofractionated adaptive MR-guided SABR for pancreatic cancer: EMERALD Phase 1 trial – Download PDF
Dr Somnath Mukherjee had the opportunity to present the results from the EMERALD Trial, which evaluated the feasibility and safety of ultra-hypofractionated SMART in treating localised pancreatic cancer (PDAC), using both three- and single-fraction schedules.
The trial was approved by the West Midlands–Black Country Research Ethics Committee, sponsored by Oxford University, and funded by the Oxford University–GenesisCare Collaboration Fund, the John Black Charitable Foundation, and the Oxford Institute of Radiation Oncology. It was administered through the Oxford Clinical Trials Office.
Oral Presentation – Download PDF
